share_log

反医药企业商业贿赂 市场监管总局出台指引

Against commercial bribery in the pharmaceutical industry, the State Administration for Market Regulation has issued guidelines.

Breakings ·  Jan 14 07:00

Recently, the State Administration for Market Regulation issued the "Compliance Guidelines for Pharmaceutical Enterprises to Prevent Commercial Bribery Risks" (hereinafter referred to as the "Guidelines"). The "Guidelines" closely align with the realities of the pharmaceutical industry, focusing on concrete descriptions and practical guidance. It summarizes and organizes commercial bribery risk points in 9 specific scenarios: academic visits and exchanges, business receptions, Consulting Services, outsourcing services, discounts and commissions, donations and sponsorships, the provision of Medical Devices for free, clinical research, and retail terminal sales, covering the entire business process in the pharmaceutical purchasing and sales field. Based on guiding pharmaceutical enterprises to accurately identify, assess, and classify commercial bribery risks, it proposes classified handling plans for these risks, guiding enterprises to fully play their primary role and effectively enhance the initiative and effectiveness of compliance management.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment

    Statement

    This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.